◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 27N0

CANNOVUM CANNABIS AG I (27N0) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

CANNOVUM CANNABIS AG I (27N0) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Berlin, Germany. Its market capitalization is roughly €1 million. In the fiscal year ended 2024-12-31, 27N0 reported €0M in revenue and (€0M) in net income.

Cannovum Cannabis AG engages in the manufacturing, wholesaling, and importing of medical cannabis products in Berlin. It also focuses on the import of medical cannabis and medical-scientific education, as well as distribution for facilitated access to cannabis-based therapies.

Interactive charts & full statements →

27N0 Revenue & Earnings History — Annual Income Statement

Income statement2024-12-312023-12-312022-12-312021-12-31
Total Revenue€0M€0M€0M€0M
Gross Profit€0M€0M€0M
Operating Income (EBIT)(€0M)(€3M)(€10M)€0M
Net Income(€0M)(€3M)(€10M)(€0M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

27N0 Free Cash Flow History

27N0 Balance Sheet History

Balance sheet2024-12-312023-12-312022-12-312021-12-31
Total Assets€1M€0M€3M€12M
Total Liabilities€0M€0M€0M€0M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 27N0 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← 2799All “0-9” companies2801 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.